VILLEJUIF, France--(BUSINESS WIRE)-- <\/p>\n
The Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine is a global network of 28 leading academic, pharma, life science, and patient advocacy organizations spanning 13 countries. WIN2013, the 5thin a series of Symposia dedicated to advancing personalized cancer medicine through global collaboration, will be held July 10-12, in Paris, France. <\/p>\n
The WIN2013 theme, Personalized Cancer Medicine: From Innovation to Implementation, will bring leaders from around the world together in a collaborative, global forum to share innovations that represent the most promising advances in personalized cancer care. <\/p>\n
Global leaders in oncology have voiced their support for WIN2013. I do not know of another forum which is designed to enable the globalization of patient specific cancer care; the discussions cover new technology through to clinical trials stated Mike Pellini, CEO of Foundation Medicine. The forum's perspective is powerful. I look forward sharing our learnings with one another so we can take one more step in the direction of truly personalized cancer care. <\/p>\n
John Mendelsohn, Director, Khalifa Institute for Personalized Cancer Medicine and Past-President, MD Anderson, noted \"The annual WIN Symposium in Paris provides a unique opportunity for leading stakeholders from academia, industry, government and advocacy groups in genomic cancer medicine to present data, exchange ideas and develop new research collaborations.\" <\/p>\n
Patient advocacy leader and breast cancer survivor Janelle Hail, Founder and CEO of the National Breast Cancer Foundation, noted, WIN has become the catalyst for global advancement in personalized cancer care. With the growing constituency of academia, industry, government, and genomic cancer medicine advocacy groups collaborating through WIN, answers will emerge to empower patients to have some part of control over their own destiny. <\/p>\n
Featuring globally recognized experts from academia, life sciences, pharma, healthcare IT, and patient advocacy, WIN2013 includes plenary sessions on: <\/p>\n
- OMICS Assays That Support Personalized Clinical Care Today <\/p>\n
- Analysis and Clinical Application of Genomics <\/p>\n
- Clinical Progress in Personalized Cancer Therapy <\/p>\n
<\/p>\n
See original here:<\/p>\n
Global Leaders in Oncology Voice Support for WIN Consortium\u2019s 2013 Symposium in Personalized Cancer Medicine<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" VILLEJUIF, France--(BUSINESS WIRE)-- The Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine is a global network of 28 leading academic, pharma, life science, and patient advocacy organizations spanning 13 countries. WIN2013, the 5thin a series of Symposia dedicated to advancing personalized cancer medicine through global collaboration, will be held July 10-12, in Paris, France. The WIN2013 theme, Personalized Cancer Medicine: From Innovation to Implementation, will bring leaders from around the world together in a collaborative, global forum to share innovations that represent the most promising advances in personalized cancer care Continue reading